Shares of iBio, Inc. (NYSE:IBIO – Get Free Report) rose 2.5% during trading on Wednesday . The company traded as high as $2.44 and last traded at $2.42. Approximately 57,343 shares changed hands during mid-day trading, a decline of 95% from the average daily volume of 1,064,661 shares. The stock had previously closed at $2.36.
iBio Price Performance
The firm’s fifty day moving average price is $2.60 and its two-hundred day moving average price is $2.27. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 0.04.
iBio (NYSE:IBIO – Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.46) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.46). As a group, research analysts predict that iBio, Inc. will post -1.74 EPS for the current fiscal year.
iBio Company Profile
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
Further Reading
- Five stocks we like better than iBio
- Industrial Products Stocks Investing
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- What is the Australian Securities Exchange (ASX)
- 2 Drone Stocks Surging from Increased Media Attention
- Profitably Trade Stocks at 52-Week Highs
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
